Advances in management of pediatric chronic immune thrombocytopenia: a narrative review

Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production. Although many pediatric patients with ITP experience spontaneous remission or reach remission within 12 months of first-line therapy, approxi...

Full description

Saved in:
Bibliographic Details
Published inJournal of yeungnam medical science Vol. 40; no. 3; pp. 241 - 246
Main Author Jae Min Lee
Format Journal Article
LanguageKorean
Published 2023
Subjects
Splenectomy
Dapsone
Rituximab
Idiopathic thrombocytopenic purpura
Thrombopoietin
Online AccessGet full text

Cover

More Information
Summary:Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production. Although many pediatric patients with ITP experience spontaneous remission or reach remission within 12 months of first-line therapy, approximately 20% progress to chronic ITP. Patients who do not respond to first-line treatment or experience frequent relapses are of great concern to physicians. This review summarizes recent treatments for second-line treatment of pediatric chronic ITP.
Bibliography:KISTI1.1003/JNL.JAKO202317936203252
ISSN:2799-8010